Internal Reference Number: FOI_8007
Date Request Received: 17/06/2024 00:00:00
Date Request Replied To: 21/06/2024 00:00:00
This response was sent via: By Email
Request Summary: Ophthalmology drugs
Request Category: Private Individuals
Question Number 1: I am researching the usage of high-cost drugs in ophthalmology. Your answers to the following questions will be highly appreciated. For the 4 months from January to April 2024, how many patients received the following intra-vitreal treatments for any eye condition: Aflibercept Bevacizumab Brolucizumab Dexamethasone Faricimab Ranibizumab - Lucentis Ranibizumab - Ongavia | |
Answer To Question 1: Aflibercept 551 Bevacizumab <5 Brolucizumab 0 Dexamethasone 13 Faricimab 294 Ranibizumab – Lucentis <5 Ranibizumab – Ongavia 0 | |
Question Number 2: For the patients above, how many were new to intra-vitreal treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments. Aflibercept Bevacizumab Brolucizumab Dexamethasone Faricimab Ranibizumab - Lucentis Ranibizumab - Ongavia | |
Answer To Question 2: Aflibercept 55 Bevacizumab <5 Brolucizumab 0 Dexamethasone <5 Faricimab 20 Ranibizumab – Lucentis 0 Ranibizumab – Ongavia 0 | |
To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.